Monoclonal Antibodies That Bind to Domain III of Dengue Virus E Glycoprotein Are the Most Efficient Blockers of Virus Adsorption to Vero Cells

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2001 Jul 20

PMID 11462053

Citations 258

Authors

W D Crill

J T Roehrig

Affiliations

Soon will be listed here.

Abstract

The specific mechanisms by which antibodies neutralize flavivirus infectivity are not completely understood. To study these mechanisms in more detail, we analyzed the ability of a well-defined set of anti-dengue (DEN) virus E-glycoprotein-specific monoclonal antibodies (MAbs) to block virus adsorption to Vero cells. In contrast to previous studies, the binding sites of these MAbs were localized to one of three structural domains (I, II, and III) in the E glycoprotein. The results indicate that most MAbs that neutralize virus infectivity do so, at least in part, by the blocking of virus adsorption. However, MAbs specific for domain III were the strongest blockers of virus adsorption. These results extend our understanding of the structure-function relationships in the E glycoprotein of DEN virus and provide the first direct evidence that domain III encodes the primary flavivirus receptor-binding motif.

Citing Articles

Omsk Hemorrhagic Fever Virus: A Comprehensive Review from Epidemiology to Diagnosis and Treatment.

Diani E, Cecchetto R, Tonon E, Mantoan M, Lotti V, Lagni A Microorganisms. 2025; 13(2).

PMID: 40005791 PMC: 11858464. DOI: 10.3390/microorganisms13020426.

The Low-Density Lipoprotein Receptor-Related Protein-1 Is Essential for Dengue Virus Infection.

Huerta V, Martin A, Sarria M, Guirola O, Yero A, Ramos Y Viruses. 2024; 16(11).

PMID: 39599807 PMC: 11599027. DOI: 10.3390/v16111692.

Identification of a dengue 2 virus envelope protein receptor in critical for viral midgut infection.

Kantor A, Talyuli O, Reid W, Alvarenga P, Booker J, Lin J Proc Natl Acad Sci U S A. 2024; 121(48):e2417750121.

PMID: 39565309 PMC: 11621822. DOI: 10.1073/pnas.2417750121.

Structure-based identification of small-molecule inhibitors that target the DIII domain of the Dengue virus glycoprotein E pan-serotypically.

Agrawal P, Arya H, Kumar G PLoS One. 2024; 19(10):e0311548.

PMID: 39453957 PMC: 11508475. DOI: 10.1371/journal.pone.0311548.

Preclinical Development of a Novel Zika Virus-like Particle Vaccine in Combination with Tetravalent Dengue Virus-like Particle Vaccines.

Rothen D, Dutta S, Krenger P, Pardini A, Vogt A, Josi R Vaccines (Basel). 2024; 12(9).

PMID: 39340083 PMC: 11435730. DOI: 10.3390/vaccines12091053.

References

van der Most R, Corver J, Strauss J . Mutagenesis of the RGD motif in the yellow fever virus 17D envelope protein. Virology. 1999; 265(1):83-95. DOI: 10.1006/viro.1999.0026. View

HUNG S, Lee P, Chen H, Chen L, Kao C, King C . Analysis of the steps involved in Dengue virus entry into host cells. Virology. 1999; 257(1):156-67. DOI: 10.1006/viro.1999.9633. View

Mandl C, Allison S, Holzmann H, Meixner T, Heinz F . Attenuation of tick-borne encephalitis virus by structure-based site-specific mutagenesis of a putative flavivirus receptor binding site. J Virol. 2000; 74(20):9601-9. PMC: 112392. DOI: 10.1128/jvi.74.20.9601-9609.2000. View

Se-Thoe S, Ling A, Ng M . Alteration of virus entry mode: a neutralisation mechanism for Dengue-2 virus. J Med Virol. 2000; 62(3):364-76. DOI: 10.1002/1096-9071(200011)62:3<364::aid-jmv9>3.0.co;2-s. View

Bhardwaj S, Holbrook M, Shope R, Barrett A, Watowich S . Biophysical characterization and vector-specific antagonist activity of domain III of the tick-borne flavivirus envelope protein. J Virol. 2001; 75(8):4002-7. PMC: 114894. DOI: 10.1128/JVI.75.8.4002-4007.2001. View

Allison S, Schalich J, Stiasny K, Mandl C, Heinz F . Mutational evidence for an internal fusion peptide in flavivirus envelope protein E. J Virol. 2001; 75(9):4268-75. PMC: 114172. DOI: 10.1128/JVI.75.9.4268-4275.2001. View

Heinz F, Mandl C, Berger R, Tuma W, Kunz C . Antibody-induced conformational changes result in enhanced avidity of antibodies to different antigenic sites on the tick-borne encephalitis virus glycoprotein. Virology. 1984; 133(1):25-34. DOI: 10.1016/0042-6822(84)90422-7. View

Henchal E, McCown J, Burke D, Seguin M, BRANDT W . Epitopic analysis of antigenic determinants on the surface of dengue-2 virions using monoclonal antibodies. Am J Trop Med Hyg. 1985; 34(1):162-9. DOI: 10.4269/ajtmh.1985.34.162. View

Gollins S, PORTERFIELD J . A new mechanism for the neutralization of enveloped viruses by antiviral antibody. Nature. 1986; 321(6067):244-6. DOI: 10.1038/321244a0. View

10.

WEIS W, Brown J, Cusack S, Paulson J, Skehel J, Wiley D . Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid. Nature. 1988; 333(6172):426-31. DOI: 10.1038/333426a0. View

11.

Roehrig J, HUNT A, Kinney R, MATHEWS J . In vitro mechanisms of monoclonal antibody neutralization of alphaviruses. Virology. 1988; 165(1):66-73. DOI: 10.1016/0042-6822(88)90659-9. View

12.

Colonno R, Callahan P, Leippe D, Rueckert R, Tomassini J . Inhibition of rhinovirus attachment by neutralizing monoclonal antibodies and their Fab fragments. J Virol. 1989; 63(1):36-42. PMC: 247654. DOI: 10.1128/JVI.63.1.36-42.1989. View

13.

Roehrig J, Johnson A, HUNT A, Bolin R, Chu M . Antibodies to dengue 2 virus E-glycoprotein synthetic peptides identify antigenic conformation. Virology. 1990; 177(2):668-75. DOI: 10.1016/0042-6822(90)90532-v. View

14.

Anderson R, King A, Innis B . Correlation of E protein binding with cell susceptibility to dengue 4 virus infection. J Gen Virol. 1992; 73 ( Pt 8):2155-9. DOI: 10.1099/0022-1317-73-8-2155. View

15.

Smith T, Olson N, Cheng R, Liu H, Chase E, Lee W . Structure of human rhinovirus complexed with Fab fragments from a neutralizing antibody. J Virol. 1993; 67(3):1148-58. PMC: 237479. DOI: 10.1128/JVI.67.3.1148-1158.1993. View

16.

Rey F, Heinz F, Mandl C, Kunz C, Harrison S . The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature. 1995; 375(6529):291-8. DOI: 10.1038/375291a0. View

17.

He R, Innis B, Nisalak A, Usawattanakul W, Wang S, Kalayanarooj S . Antibodies that block virus attachment to Vero cells are a major component of the human neutralizing antibody response against dengue virus type 2. J Med Virol. 1995; 45(4):451-61. DOI: 10.1002/jmv.1890450417. View

18.

Hiramatsu K, Tadano M, Men R, Lai C . Mutational analysis of a neutralization epitope on the dengue type 2 virus (DEN2) envelope protein: monoclonal antibody resistant DEN2/DEN4 chimeras exhibit reduced mouse neurovirulence. Virology. 1996; 224(2):437-45. DOI: 10.1006/viro.1996.0550. View

19.

Kinney R, Butrapet S, Chang G, Tsuchiya K, Roehrig J, Bhamarapravati N . Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53. Virology. 1997; 230(2):300-8. DOI: 10.1006/viro.1997.8500. View

20.

Chen Y, Maguire T, Hileman R, Fromm J, Esko J, Linhardt R . Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat Med. 1997; 3(8):866-71. DOI: 10.1038/nm0897-866. View